scholarly journals Optimizing the identification of risk-relevant mutations by multigene panel testing in selected hereditary breast/ovarian cancer families

2017 ◽  
Vol 7 (1) ◽  
pp. 46-55 ◽  
Author(s):  
Anna Coppa ◽  
Arianna Nicolussi ◽  
Sonia D'Inzeo ◽  
Carlo Capalbo ◽  
Francesca Belardinilli ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Hereditary Breast Ovarian Cancer ◽  
Panel Testing ◽  
Multigene Panel Testing ◽  
Multigene Panel

Evaluation of criteria for genetic study of hereditary breast and ovarian cancer BRCAX families by multigene panel testing

2019 ◽  
Vol 493 ◽  
pp. S576-S577
Author(s):  
V. Castillo-Guardiola ◽  
M.D. Sarabia-Meseguer ◽  
J.A. Macías-Cerrolaza ◽  
Á. García-Aliaga ◽  
L. Rosado-Jiménez ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Genetic Study ◽  
Breast And Ovarian Cancer ◽  
Panel Testing ◽  
Multigene Panel Testing ◽  
Multigene Panel

The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e13116-e13116
Author(s):  
Sarab Lizard ◽  
Marie Eliade ◽  
Jeremy Skrzypski ◽  
Amandine Baurand ◽  
Caroline Jacquot ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Breast And Ovarian Cancer ◽  
Panel Testing ◽  
Multigene Panel Testing ◽  
Multigene Panel

scholarly journals The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?

Oncotarget ◽  
2016 ◽  
Vol 8 (2) ◽  
pp. 1957-1971 ◽  
Author(s):  
Marie Eliade ◽  
Jeremy Skrzypski ◽  
Amandine Baurand ◽  
Caroline Jacquot ◽  
Geoffrey Bertolone ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Breast And Ovarian Cancer ◽  
Panel Testing ◽  
Multigene Panel Testing ◽  
Multigene Panel

Abstract 1287: Multigene panel testing and risk estimates in 10,233 ovarian cancer cases

2017 ◽  
Author(s):  
Jenna Lilyquist ◽  
Holly LaDuca ◽  
Eric Polley ◽  
Hermela Shimelis ◽  
Chunling Hu ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Panel Testing ◽  
Risk Estimates ◽  
Multigene Panel Testing ◽  
Multigene Panel

scholarly journals A Systematic Comparison of Traditional and Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Genes in More Than 1000 Patients

2015 ◽  
Vol 17 (5) ◽  
pp. 533-544 ◽  
Author(s):  
Stephen E. Lincoln ◽  
Yuya Kobayashi ◽  
Michael J. Anderson ◽  
Shan Yang ◽  
Andrea J. Desmond ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Genes ◽  
Breast And Ovarian Cancer ◽  
Systematic Comparison ◽  
Panel Testing ◽  
Multigene Panel Testing ◽  
Multigene Panel

Initial Results of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer and Lynch Syndrome

2015 ◽  
Vol 81 (10) ◽  
pp. 941-944 ◽  
Author(s):  
Dt R. Howarth ◽  
Sharon S. Lum ◽  
Pamela Esquivel ◽  
Carlos A. Garberoglio ◽  
Maheswari Senthil ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Genetic Testing ◽  
Breast And Ovarian Cancer ◽  
Variants Of Uncertain Significance ◽  
Panel Testing ◽  
Pathogenic Mutations ◽  
Uncertain Significance ◽  
Multigene Panel Testing ◽  
The Impact ◽  
Multigene Panel

Multigene panel testing for hereditary cancer risk has recently become commercially available; however, the impact of its use on patient care is undefined. We sought to evaluate results from implementation of panel testing in a multidisciplinary cancer center. We performed a retrospective review of consecutive patients undergoing genetic testing after initiating use of multigene panel testing at Loma Linda University Medical Center. From February 13 to August 25, 2014, 92 patients were referred for genetic testing based on National Comprehensive Cancer Network guidelines. Testing was completed in 90 patients. Overall, nine (10%) pathogenic mutations were identified: five BRCA1/2, and four in non-BRCA loci. Single-site testing identified one BRCA1 and one BRCA2 mutation. The remaining mutations were identified by use of panel testing for hereditary breast and ovarian cancer. There were 40 variants of uncertain significance identified in 34 patients. The use of panel testing more than doubled the identification rate of clinically significant pathogenic mutations that would have been missed with BRCA testing alone. The large number of variants of uncertain significance identified will require long-term follow-up for potential reclassification. Multigene panel testing provides additional information that may improve patient outcomes.

Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care

2016 ◽  
Vol 160 (3) ◽  
pp. 393-410 ◽  
Author(s):  
Rossella Graffeo ◽  
Luca Livraghi ◽  
Olivia Pagani ◽  
Aron Goldhirsch ◽  
Ann H. Partridge ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patient ◽  
Patient Care ◽  
Ovarian Cancer Patient ◽  
Breast And Ovarian Cancer ◽  
Panel Testing ◽  
Multigene Panel Testing ◽  
Multigene Panel

Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings

2018 ◽  
Vol 144 (12) ◽  
pp. 2495-2513 ◽  
Author(s):  
Sandra Bonache ◽  
Irene Esteban ◽  
Alejandro Moles-Fernández ◽  
Anna Tenés ◽  
Laura Duran-Lozano ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Panel Testing ◽  
Multigene Panel Testing ◽  
Multigene Panel
Sign in / Sign up

Export Citation Format

Share Document